• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

1958年至1991年间瑞典的垂体腺瘤:发病率、生存率和死亡率。

Pituitary adenomas in Sweden between 1958 and 1991: incidence, survival, and mortality.

作者信息

Nilsson B, Gustavasson-Kadaka E, Bengtsson B A, Jonsson B

机构信息

Department of Cancer Epidemiology, Karolinska University Hospital, Stockholm, Sweden.

出版信息

J Clin Endocrinol Metab. 2000 Apr;85(4):1420-5. doi: 10.1210/jcem.85.4.6498.

DOI:10.1210/jcem.85.4.6498
PMID:10770176
Abstract

The objective of the present study was to determine the incidence of pituitary adenomas (PAs) and the associated rates and causes of mortality in a large population. The study population comprised 2279 patients (1010 women and 1269 men) of all individuals (n = 3321) with pituitary tumors included in the Swedish Cancer Registry between 1958 and 1991. The mean age (+/-SD) at diagnosis was 52.3 +/-15.7 yr. The age-standardized incidence of PA increased significantly from approximately 6 cases/million inhabitants in 1958 to 11 cases/ million in 1991. The age-specific incidence peaked between 60-70 yr of age in both sexes. Excess mortality was found in the study population. The total number of deaths was 842. The standardized mortality ratio (SMR) for the study population was 2.0. The SMR for women (2.3) was significantly (P < 0.01) higher than that for men (1.9). Cardiovascular diseases were the most common cause of mortality among patients, accounting for 346 deaths (SMR, 1.6). The difference between the sexes was significant (men, 1.4; women, 1.8; P < 0.05). Cerebrovascular death occurred in 97 patients (SMR, 2.4), with no significant difference between men (SMR, 2.5) and women (SMR, 2.2). Excess mortality was also observed for tumors, endocrine diseases, and gastrointestinal diseases. These findings suggest that the annual incidence of PA is increasing. Possible explanations are improved diagnostic skill and/or increased awareness of pituitary diseases among physicians. However, a real increase in the incidence of PA cannot be ruled out.

摘要

本研究的目的是确定在一大群人中垂体腺瘤(PA)的发病率以及相关的死亡率和死亡原因。研究人群包括1958年至1991年间瑞典癌症登记处登记的所有垂体肿瘤患者(n = 3321)中的2279例患者(1010名女性和1269名男性)。诊断时的平均年龄(±标准差)为52.3±15.7岁。PA的年龄标准化发病率从1958年的约6例/百万居民显著增加到1991年的11例/百万。两性的年龄特异性发病率在60 - 70岁之间达到峰值。在研究人群中发现了超额死亡率。死亡总数为842例。研究人群的标准化死亡比(SMR)为2.0。女性的SMR(2.3)显著高于男性(1.9)(P < 0.01)。心血管疾病是患者中最常见的死亡原因,占346例死亡(SMR,1.6)。两性之间的差异显著(男性,1.4;女性,1.8;P < 0.05)。97例患者发生脑血管死亡(SMR,2.4),男性(SMR,2.5)和女性(SMR,2.2)之间无显著差异。在肿瘤、内分泌疾病和胃肠道疾病方面也观察到超额死亡率。这些发现表明PA的年发病率正在增加。可能的解释是诊断技术的提高和/或医生对垂体疾病认识的增加。然而,不能排除PA发病率的实际增加。

相似文献

1
Pituitary adenomas in Sweden between 1958 and 1991: incidence, survival, and mortality.1958年至1991年间瑞典的垂体腺瘤:发病率、生存率和死亡率。
J Clin Endocrinol Metab. 2000 Apr;85(4):1420-5. doi: 10.1210/jcem.85.4.6498.
2
Excess Mortality in Women and Young Adults With Nonfunctioning Pituitary Adenoma: A Swedish Nationwide Study.女性和青年非功能性垂体腺瘤患者的超额死亡率:一项瑞典全国性研究。
J Clin Endocrinol Metab. 2015 Jul;100(7):2651-8. doi: 10.1210/jc.2015-1475. Epub 2015 May 6.
3
The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011.2001-2011 年期间瑞典西部垂体腺瘤的发病率。
Eur J Endocrinol. 2014 Oct;171(4):519-26. doi: 10.1530/EJE-14-0144. Epub 2014 Aug 1.
4
National incidence and prevalence of TSH-secreting pituitary adenomas in Sweden.瑞典促甲状腺激素(TSH)分泌型垂体腺瘤的发病率和患病率。
J Clin Endocrinol Metab. 2013 Feb;98(2):626-35. doi: 10.1210/jc.2012-3362. Epub 2013 Jan 7.
5
Time trends of mortality in patients with non-functioning pituitary adenoma: a Swedish nationwide study.无功能垂体腺瘤患者死亡率的时间趋势:一项瑞典全国性研究。
Pituitary. 2017 Apr;20(2):218-224. doi: 10.1007/s11102-016-0764-8.
6
Excess mortality and morbidity in patients with craniopharyngioma, especially in patients with childhood onset: a population-based study in Sweden.颅咽管瘤患者的超额死亡率和发病率,尤其是儿童期发病的患者:瑞典一项基于人群的研究
J Clin Endocrinol Metab. 2015 Feb;100(2):467-74. doi: 10.1210/jc.2014-3525. Epub 2014 Nov 6.
7
Incidence and familial risks in pituitary adenoma and associated tumors.垂体腺瘤及相关肿瘤的发病率和家族风险。
Endocr Relat Cancer. 2007 Mar;14(1):103-9. doi: 10.1677/ERC-06-0008.
8
Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK).在英国牛津郡的班伯里(Banbury,Oxfordshire,UK)进行的一项基于社区的垂体腺瘤患病率横断面研究。
Clin Endocrinol (Oxf). 2010 Mar;72(3):377-82. doi: 10.1111/j.1365-2265.2009.03667.x. Epub 2009 Jul 24.
9
Postoperative mortality in parathyroid surgery in Sweden during five decades: improved outcome despite older patients.瑞典五十年间甲状旁腺手术的术后死亡率:尽管患者年龄增大,但结局仍有所改善。
Eur J Endocrinol. 2009 Feb;160(2):295-9. doi: 10.1530/EJE-08-0523. Epub 2008 Nov 28.
10
Pituitary adenomas in northern Sweden: a study on therapy choices and the risk of second primary tumours.瑞典北部的垂体腺瘤:关于治疗选择及第二原发性肿瘤风险的研究
Clin Endocrinol (Oxf). 2008 May;68(5):780-5. doi: 10.1111/j.1365-2265.2007.03118.x. Epub 2007 Nov 2.

引用本文的文献

1
Fracture risks in patients aged 50 years and older with panhypopituitarism: a nationwide cohort study.50岁及以上全垂体功能减退患者的骨折风险:一项全国性队列研究。
Osteoporos Int. 2025 Jul 8. doi: 10.1007/s00198-025-07574-2.
2
Sex-Specific Cardiovascular Risks and Mortality in Patients with Panhypopituitarism: A Nationwide Cohort Study.全垂体功能减退症患者的性别特异性心血管风险和死亡率:一项全国性队列研究。
Endocrinol Metab (Seoul). 2025 Jun;40(3):469-483. doi: 10.3803/EnM.2024.2176. Epub 2025 Feb 11.
3
Replacement with sex steroids in hypopituitary men and women: implications for gender differences in morbidities and mortality.
垂体功能减退的男性和女性用性激素替代治疗:对发病率和死亡率的性别差异的影响。
Rev Endocr Metab Disord. 2024 Oct;25(5):839-854. doi: 10.1007/s11154-024-09897-7. Epub 2024 Oct 7.
4
Excess mortality in patients with non-functioning pituitary adenoma: a systematic review and meta-analysis.无功能性垂体腺瘤患者的超额死亡率:系统评价和荟萃分析。
J Endocrinol Invest. 2024 Sep;47(9):2143-2155. doi: 10.1007/s40618-024-02356-9. Epub 2024 Mar 19.
5
Clinical presentation and recurrence of pituitary neuroendocrine tumors: results from a single referral center in Colombia.垂体神经内分泌肿瘤的临床表现与复发:来自哥伦比亚一家转诊中心的结果
J Endocrinol Invest. 2023 Nov;46(11):2275-2286. doi: 10.1007/s40618-023-02080-w. Epub 2023 Mar 31.
6
Pituitary adenomas and cerebrovascular disease: A review on pathophysiology, prevalence, and treatment.垂体腺瘤与脑血管病:病理生理学、患病率和治疗的综述。
Front Endocrinol (Lausanne). 2022 Dec 13;13:1064216. doi: 10.3389/fendo.2022.1064216. eCollection 2022.
7
Pituitary Carcinoma Diagnosis and Survival Improvement, with Affordable Care Act Correlation: A SEER Database Study.垂体癌的诊断与生存改善及与《平价医疗法案》的相关性:一项监测、流行病学和最终结果(SEER)数据库研究
J Neurol Surg B Skull Base. 2021 Feb 4;83(3):305-311. doi: 10.1055/s-0040-1722747. eCollection 2022 Jun.
8
Pituitary Adenoma Incidence, Management Trends, and Long-term Outcomes: A 30-Year Population-Based Analysis.垂体腺瘤的发病率、治疗趋势和长期预后:一项基于人群的 30 年分析。
Mayo Clin Proc. 2022 Oct;97(10):1861-1871. doi: 10.1016/j.mayocp.2022.03.017. Epub 2022 Jun 24.
9
Clinical Biology of the Pituitary Adenoma.垂体腺瘤的临床生物学。
Endocr Rev. 2022 Nov 25;43(6):1003-1037. doi: 10.1210/endrev/bnac010.
10
Incidence, demographics, and survival of patients with primary pituitary tumors: a SEER database study in 2004-2016.2004-2016 年基于 SEER 数据库的原发性垂体瘤患者发病情况、人口统计学特征和生存分析。
Sci Rep. 2021 Jul 26;11(1):15155. doi: 10.1038/s41598-021-94658-8.